As of 2026-03-14, the Relative Valuation of Syndax Pharmaceuticals Inc (SNDX) is (74.96) USD. This relative valuation is based on P/E multiples. With the latest stock price at 23.50 USD, the upside of Syndax Pharmaceuticals Inc based on Relative Valuation is -419.0%.
The range of the Relative Valuation is (67.13) - (79.54) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.4x - 26.5x | 23.4x |
| Forward P/E multiples | 20.4x - 24.2x | 22.3x |
| Fair Price | (67.13) - (79.54) | (74.96) |
| Upside | -385.6% - -438.5% | -419.0% |
| Date | P/E |
| 2026-03-13 | -7.16 |
| 2026-03-12 | -7.30 |
| 2026-03-11 | -7.44 |
| 2026-03-10 | -7.36 |
| 2026-03-09 | -7.27 |
| 2026-03-06 | -6.72 |
| 2026-03-05 | -6.57 |
| 2026-03-04 | -6.58 |
| 2026-03-03 | -6.52 |
| 2026-03-02 | -6.74 |
| 2026-02-27 | -6.61 |
| 2026-02-26 | -6.29 |
| 2026-02-25 | -6.32 |
| 2026-02-24 | -6.25 |
| 2026-02-23 | -6.06 |
| 2026-02-20 | -6.00 |
| 2026-02-19 | -6.28 |
| 2026-02-18 | -6.17 |
| 2026-02-17 | -6.19 |
| 2026-02-13 | -6.24 |
| 2026-02-12 | -6.44 |
| 2026-02-11 | -6.61 |
| 2026-02-10 | -6.49 |
| 2026-02-09 | -6.45 |
| 2026-02-06 | -6.40 |
| 2026-02-05 | -6.14 |
| 2026-02-04 | -6.22 |
| 2026-02-03 | -6.47 |
| 2026-02-02 | -6.50 |
| 2026-01-30 | -6.18 |
| 2026-01-29 | -6.27 |
| 2026-01-28 | -6.26 |
| 2026-01-27 | -6.49 |
| 2026-01-26 | -6.52 |
| 2026-01-23 | -6.17 |
| 2026-01-22 | -6.33 |
| 2026-01-21 | -6.25 |
| 2026-01-20 | -6.16 |
| 2026-01-16 | -6.25 |
| 2026-01-15 | -6.29 |
| 2026-01-14 | -6.53 |
| 2026-01-13 | -6.23 |
| 2026-01-12 | -6.31 |
| 2026-01-09 | -6.39 |
| 2026-01-08 | -6.51 |
| 2026-01-07 | -6.73 |
| 2026-01-06 | -6.19 |
| 2026-01-05 | -6.16 |
| 2026-01-02 | -6.49 |
| 2025-12-31 | -6.40 |